Table 1.

Studies of Thyroid Dysfunction (TD) Following Pediatric HCT^*

	Reference	Incidence of TD	Number	Disease	Conditioning	F/U Median (range)	Risk Factors
Michel et al. 1997	5	9%	26	AML	BU + CY	5.9 yrs (1–9)	None
Afify et al. 2000	6	0%	23	AML only	BU + CY	4.9 yrs (2–10)	None
Slatter et al. 2004	7	11%	83	PID only	BU + CY	NR (2–4.5)	Autoimmunity?
Ishiguro et al. 2004	4	30%	147	Varied	Varied	11.1 yrs (5.8–21.5)	Age <10 yrs
Berger et al. 2005	8	27% 29%	101 14	ALL only ALL only	FTBI + Chemo BU + Chemo	8.5 yrs (5–16.5)	Age <10 yrs; Transplant in >CR1
Leung et al. 2007	9	34%	155	Varied	Varied	9 yrs (3.1–15.9)	Young age; higher dose TBI
Sanders et al. 2008	2	32% 23%	538 108	Varied Varied	FTBI + CY BU + Chemo	NR (1–30)	Age <10 yrs; Malignancy
Dvorak et al. 2008	10	8%	25	Varied	Varied	6.5 yrs (1–15)	Only seen in FTBI recipients
Bailey et al. 2008	3	52%	33	Mainly malignancy	FTBI + Chemo	4 yrs (0.5–8.5)	Unrelated Donors
Sanders et al. 2011	11	12%	137	SAA only	CY/CY + TBI	21.8 yrs (1–38.1)	TBI

^*Studies including only unfractionated TBI were excluded

AML Acute Myeloblastic Leukemia

ALL Acute Lymphoblastic Leukemia

SAA Severe Aplastic Anemia

PID Primary Immunodeficiency

BU Busulfan

CY Cyclophosphamide

FTBI Fractionated Total Body Irradiation

NR Not Reported